Triple vs. Double Therapy in naïves HIV-Infected Patients
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to clarify whether if starting antiretroviral treatment based
on dual therapy (DTG + 3TC) could provide less control of residual HIV replication and,
therefore, a detriment on immune activation and inflammation compared to starting with triple
therapy, and could worsen the patients' long-term prognosis. For this purpose, the
investigator has designed a randomized clinical trial where will assess the immunological
recovery (CD4+/CD8+), immune activation, proliferation, senescence and apoptosis in T
lymphocytes CD4+ and CD8+ cells by flow cytometry, the immune activation of monocytes/
macrophages and plasma concentrations of various inflammatory mediators by ELISAS, and the
thymic function, the cellular reservoir of HIV and the degree of HIV DNA transcription by
digital dropped PCR.